Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.48 |
| ▸ | CYP19A1 known ✓ | P11511 | 5/20 | 0.42 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.41 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4233791 | 1.00 | ADRB2 (0.48) | ADRB2CYP2A6ALDH1A1NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL1001689 | 1.00 | ADRB2 (0.48) | ADRB2CYP2A6ALDH1A1NOS3NOS1 | |
| SCHEMBL6814147 | 0.98 | ADRB2 (0.50) | ADRB2CYP2A6ALDH1A1NOS3NOS1 | |
| SCHEMBL320272 | 0.98 | ADRB2 (0.50) | ADRB2CYP2A6ALDH1A1NOS3NOS1 | |
| SCHEMBL319930 | 0.98 | ADRB2 (0.50) | ADRB2CYP2A6ALDH1A1NOS3NOS1 | |
| SCHEMBL29225795 | 0.91 | KIF11 (0.48) | ADRB2CYP2A6ALDH1A1CYP19A1LOXL2 | |
| SCHEMBL29225796 | 0.91 | KIF11 (0.48) | ADRB2CYP2A6ALDH1A1CYP19A1LOXL2 | |
| SCHEMBL7778714 | 0.83 | KIF11 (0.59) | ADRB2CYP2A6ALDH1A1CYP19A1PDE2A | |
| Hydrochloric Acid SCHEMBL30098314 | 0.81 | CYP19A1 (0.45) | CYP2A6ALDH1A1NOS3NOS1CYP19A1 | |
| SCHEMBL7799578 | 0.78 | CYP2A6 (0.52) | CYP2A6ALDH1A1NOS3NOS1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | NXERA PHARMA UK LIMITED (GB) | 2025-12-09 | — | — | US | disclosed |
| EP-4146645-B1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2025-06-25 | — | — | EP | disclosed |
| US-20250179036-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2025-06-05 | — | — | US | disclosed |
| CN-119855814-A | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP 4) agonists for the treatment of gastrointestinal and pulmonary diseases | 奈克斯拉制药英国有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-12275716-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| CN-114585603-B | Prostaglandin EP4Receptor antagonist compounds | 奈克斯拉制药英国有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-115461338-B | 3-azabicyclo (3.1.0) hexane derivatives having KDM5 inhibitory activity and uses thereof | 小野药品工业株式会社 | 2024-02-20 | — | — | CN | disclosed |
| CN-117551089-A | Estrogen receptor proteolytic modulators and related methods of use | 阿尔维纳斯运营股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4302764-A2 | C17, C20, AND C21 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | Sage Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-110612297-B | Estrogen receptor proteolytic modulators and related methods of use | 阿尔维纳斯运营股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-115461338-A | 3-azabicyclo (3.1.0) hexane derivatives having KDM5 inhibitory activity and uses thereof | 小野药品工业株式会社 | 2022-12-09 | — | — | CN | disclosed |
| US-20220267305-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-08-25 | — | — | US | disclosed |
| US-11396525-B2 | C17, C20, and C21 substituted neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| WO-2022020288-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2020-06-25 | — | — | US | disclosed |
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190248831-A1 | C17, C20, AND C21 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. (US) | 2019-08-15 | — | — | US | disclosed |
| US-20180237418-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-08-23 | — | — | US | disclosed |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | ADRB2 3399/4885CYP19A1 276/4885CA2 3519/4885 |
| US-20190248831-A1 | C17, C20, AND C21 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | CNR1, CNR2, GABRA1 | ADRB2 56/4885CYP19A1 144/4885CA2 687/4885 |
| US-11396525-B2 | C17, C20, and C21 substituted neuroactive steroids and their methods of use | CNR1, CNR2, GABRA1 | ADRB2 56/4885CYP19A1 144/4885CA2 687/4885 |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | ADRB2 3399/4885CYP19A1 276/4885CA2 3519/4885 |
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | PTGER4, PTGER1, PTGER2 | ADRB2 85/4885CYP19A1 1589/4885CA2 1914/4885 |
| US-12275716-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | ADRB2 3399/4885CYP19A1 276/4885CA2 3519/4885 |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | ADRB2 3399/4885CYP19A1 276/4885CA2 3519/4885 |
| US-20220267305-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | ADRB2 3399/4885CYP19A1 276/4885CA2 3519/4885 |
| US-20180237418-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | ADRB2 3399/4885CYP19A1 276/4885CA2 3519/4885 |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | THPO, MPL, MCL1 | ADRB2 3421/4885CYP19A1 1722/4885CA2 3711/4885 |
| US-20250179036-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, PTGER2 | ADRB2 85/4885CYP19A1 1589/4885CA2 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.